BidaskClub lowered shares of FibroGen (NASDAQ:FGEN) from a hold rating to a sell rating in a research note published on Thursday morning.

A number of other equities analysts have also issued reports on FGEN. William Blair restated an outperform rating on shares of FibroGen in a research note on Wednesday, August 9th. ValuEngine lowered FibroGen from a hold rating to a sell rating in a research note on Friday, December 1st. Stifel Nicolaus restated a buy rating and issued a $80.00 target price on shares of FibroGen in a research note on Thursday, September 14th. Mizuho initiated coverage on FibroGen in a research note on Wednesday, October 4th. They issued a neutral rating and a $61.00 target price for the company. Finally, Jefferies Group restated a buy rating and issued a $75.00 target price on shares of FibroGen in a research note on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. FibroGen currently has a consensus rating of Buy and an average target price of $65.67.

Shares of FibroGen (NASDAQ:FGEN) opened at $46.40 on Thursday. FibroGen has a twelve month low of $19.25 and a twelve month high of $60.15. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16.

In other news, Director Gerald Lema acquired 3,500 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were bought at an average cost of $46.70 per share, for a total transaction of $163,450.00. Following the acquisition, the director now owns 3,500 shares in the company, valued at approximately $163,450. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jorma Routti sold 12,000 shares of FibroGen stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $47.25, for a total value of $567,000.00. Following the completion of the sale, the director now owns 133,840 shares in the company, valued at $6,323,940. The disclosure for this sale can be found here. Insiders have sold a total of 397,131 shares of company stock worth $21,109,380 over the last 90 days. Insiders own 13.60% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. SG Americas Securities LLC raised its position in shares of FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares during the period. Cornerstone Capital Management Holdings LLC. raised its position in shares of FibroGen by 1.7% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock valued at $939,000 after buying an additional 474 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of FibroGen by 15.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 696 shares during the period. Tudor Investment Corp ET AL raised its position in shares of FibroGen by 7.1% during the 2nd quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock valued at $391,000 after buying an additional 799 shares during the period. Finally, Amalgamated Bank raised its position in FibroGen by 15.0% in the third quarter. Amalgamated Bank now owns 8,423 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 1,097 shares during the period. Institutional investors and hedge funds own 57.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “FibroGen (FGEN) Downgraded by BidaskClub to “Sell”” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/fibrogen-fgen-downgraded-by-bidaskclub-to-sell/1756874.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.